EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A SARS‐CoV‐2 EG.5 mRNA vaccine induces a broad‐spectrum immune response in mice

Hongyu Wang, Qinhua Peng, Xinxian Dai, Zhifang Ying, Xiaohong Wu, Xinyu Liu, Hongshan Xu, Jia Li, Leitai Shi, Jingjing Liu, Yunpeng Wang, Danhua Zhao und 8 weitere

MedComm · 2025-01 · 6 (1)

DOI: 10.1002/mco2.779 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MedComm, online erschienen am 02.01.2025. Verfasst von Hongyu Wang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Arboviral Vaccine National Institutes for Food and Drug Control Beijing China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emerging of emergent SARS‐CoV‐2 subvariants has reduced the protective efficacy of COVID‐19 vaccines. Therefore, novel COVID‐19 vaccines targeting these emergent variants are needed. We designed and prepared CoV072, an mRNA‐based vaccine against SARS‐CoV‐2 Omicron (EG.5) and other emergent SARS‐CoV‐2 subvariants that encodes the EG.5 spike protein. Six‐week‐old female BALB/C mice were used to assess humoral and cellular immune responses and cross‐reactive neutralizing activity against various SARS‐CoV‐2 subvariants. Meanwhile different immunization strategies and doses were performed to detect the immunogenicity of this mRNA vaccine. Our results show that two doses of 5 µg CoV072 or a single dose of 15 µg CoV072 both induced broad‐spectrum cross‐protection ability in mice. Compared with a single dose of 15 µg CoV072, two doses of 5 µg COV072 exhibited higher levels of pseudovirus neutralizing antibody (PNAb) and cross‐reactive IgG responses to multiple variants. Moreover, higher levels of neutralizing antibody (NAb) against live XBB and EG.5 variants were also induced. Th1‐biased cellular immune response was induced in all vaccination groups. The antigen design and immunization strategy of this study have reference significance for the research of the next generation of COVID‐19 vaccine and other vaccines.

Schlagwörter

Stichwörter der Autor:innen

SARS‐CoV‐2 variantsimmunization strategiesimmunogenicitymRNA‐based vaccines

Autor:innen und Institutionen

  • Department of Arboviral Vaccine National Institutes for Food and Drug Control Beijing China.
  • Etiology Laboratory,National Vaccine and Serum Institute Beijing China.
  • Division of Respiratory Virus Vaccines National Institutes for Food and Drug Control Beijing China.

Förderung

  • National Key Research and Development Program of China

Zitieren

APA

Wang, H., Peng, Q., Dai, X., Ying, Z., Wu, X., Liu, X., Xu, H., Li, J., Shi, L., Liu, J., Wang, Y., Zhao, D., Huang, Y., Yang, L., Yang, R., Yue, G., Suo, Y., Ye, Q., Cao, S., & Li, Y. (2025). A SARS‐CoV‐2 EG.5 mRNA vaccine induces a broad‐spectrum immune response in mice. MedComm, 6(1). https://doi.org/10.1002/mco2.779

Vancouver

Wang H, Peng Q, Dai X, Ying Z, Wu X, Liu X, et al. A SARS‐CoV‐2 EG.5 mRNA vaccine induces a broad‐spectrum immune response in mice. MedComm. 2025;6(1). doi:10.1002/mco2.779

BibTeX
@article{Wang2025,
  author = {Wang, Hongyu and Peng, Qinhua and Dai, Xinxian and Ying, Zhifang and Wu, Xiaohong and Liu, Xinyu and Xu, Hongshan and Li, Jia and Shi, Leitai and Liu, Jingjing and Wang, Yunpeng and Zhao, Danhua and Huang, Yanqiu and Yang, Lihong and Yang, Ren and Yue, Guangzhi and Suo, Yue and Ye, Qiang and Cao, Shouchun and Li, Yuhua},
  title = {A SARS‐CoV‐2 EG.5 mRNA vaccine induces a broad‐spectrum immune response in mice},
  journal = {MedComm},
  year = {2025},
  volume = {6},
  number = {1},
  doi = {10.1002/mco2.779}
}
Kostenlos starten →